New class of precision antimicrobials redefines role of Clostridium difficile S-layer in virulence and viability

See allHide authors and affiliations

Science Translational Medicine  06 Sep 2017:
Vol. 9, Issue 406, eaah6813
DOI: 10.1126/scitranslmed.aah6813

Article Information

vol. 9 no. 406

Print ISSN: 
Online ISSN: 
  • Received for publication July 31, 2016
  • Resubmitted February 6, 2017
  • Accepted for publication April 13, 2017
  • .

Author Information

  1. Joseph A. Kirk1,
  2. Dana Gebhart2,
  3. Anthony M. Buckley3,
  4. Stephen Lok2,
  5. Dean Scholl2,
  6. Gillian R. Douce3,
  7. Gregory R. Govoni2,* and
  8. Robert P. Fagan1,*
  1. 1Krebs Institute, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield S10 2TN, UK.
  2. 2AvidBiotics Corp., South San Francisco, CA 94080, USA.
  3. 3Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.
  1. *Corresponding author. Email: ggovons{at} (G.R.G.); r.fagan{at} (R.P.F.)


Article usage

Article usage:

No statistics are available.

Stay Connected to Science Translational Medicine

Navigate This Article